Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fr-173657 SCHEMBL29473494 | 1.00 | BDKRB2 (1.00) | BDKRB2 | |
| Fr-173657 SCHEMBL3718364 | 1.00 | BDKRB2 (1.00) | BDKRB2 | |
| Fr-173657 SCHEMBL7246238 | 0.99 | BDKRB2 (0.99) | BDKRB2 | |
| Fr-173657 SCHEMBL7246230 | 0.99 | BDKRB2 (0.99) | BDKRB2 | |
| SCHEMBL7742468 | 0.95 | BDKRB2 (0.91) | BDKRB2 | |
| SCHEMBL7742459 | 0.95 | BDKRB2 (0.91) | BDKRB2 | |
| SCHEMBL8812166 | 0.95 | BDKRB2 (0.90) | BDKRB2 | |
| SCHEMBL7749804 | 0.93 | BDKRB2 (0.87) | BDKRB2 | |
| SCHEMBL7748002 | 0.93 | BDKRB2 (0.87) | BDKRB2 | |
| SCHEMBL7749801 | 0.93 | BDKRB2 (0.87) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | claimed |
| EP-2303268-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | LUSO FARMACO INST (IT) | 2012-06-20 | — | — | EP | claimed |
| JP-2011527296-A | — | — | 2011-10-27 | — | — | JP | claimed |
| EP-2222275-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | LUSO FARMACO INST (IT) | 2011-10-19 | — | — | EP | claimed |
| EP-1901775-B1 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | JERINI AG (DE) | 2011-08-24 | — | — | EP | claimed |
| US-20110112011-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2011-05-12 | — | — | US | claimed |
| EP-2303268-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | Istituto Luso Farmaco d'Italia S.p.A. (IT) | 2011-04-06 | — | — | EP | claimed |
| EP-2222275-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | Istituto Luso Farmaco d'Italia S.p.A. (IT) | 2010-09-01 | — | — | EP | claimed |
| WO-2010003601-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | INSTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2010-01-14 | — | — | WO | claimed |
| WO-2009065507-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2009-05-28 | — | — | WO | claimed |
| US-20030120076-A1 | Vitreous form | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-26 | — | — | US | claimed |
| US-6531480-B1 | Administering topically to eye to treat ophthalmic allergy diseases or disorders | ALCON MANUFACTURING, LTD. | 2003-03-11 | — | — | US | claimed |
| US-6509468-B1 | FR 173657 used as an antiallergen, antiinflammatory agent, antishock agent, or analgesic; autoimmune diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-21 | — | — | US | claimed |
| US-6500831-B1 | APPLYING 3-(6-ACETAMIDO-3-PYRIDYL)N-(N-(2,4-DICHLORO-3-((2-METHYL-8 -QUINOLINYL)OXYMETHYL)PHENYL)-N-METHYLAMINO-CARBONYL METHYL)ACRYLAMIDE), TO THE EYES AS HYPOTENSIVE AGENTS AND FOR PROPHYLAXIS OF VISION DEFECTS | ALCON MANUFACTURING, LTD. | 2002-12-31 | — | — | US | claimed |
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | claimed |
| EP-1123288-A1 | VITREOUS FORM OF KNOWN BRADYKININ ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-16 | — | — | EP | claimed |
| US-6169095-B1 | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | claimed |
| WO-2000023439-A1 | VITREOUS FORM OF KNOWN BRADYKININ ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-27 | — | — | WO | claimed |
| WO-1999051245-A1 | NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS FOR USE IN TREATING OPHTHALMIC DISEASES AND DISORDERS | ALCON LABORATORIES, INC. (US) | 1999-10-14 | — | — | WO | claimed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120076-A1 | Vitreous form | FAM162A, VEGFA, WEE2 | BDKRB2 3121/4885 |
| US-20110112011-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | BDKRB2, PTGER2, PTGER1 | BDKRB2 1/4885 |
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | BDKRB2, BDKRB1, HRH2 | BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.